Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Givaudan Q1 Sales Rise; Expects Growth Ahead - Update

Givaudan AG (GVDBF.PK), a Swiss manufacturer of fragrance and flavour products, on Wednesday said it experienced a strong start to the year, with first-quarter sales increasing 4.7 percent. Both the Fragrance and flavour divisions posted higher sales. The company added that it expects further growth over the medium term.

In the first three months of 2012, Givaudan's sales totaled 1.06 billion Swiss francs, higher than prior year's 1.01 billion francs. In local currencies, sales grew 8.4 percent.

Givaudan noted that it started the year with "a continued strong business momentum with a full project pipeline and win rates sustained at a high level. The company continues to successfully implement price increases in collaboration with its customers to compensate the increases in input costs."

Fragrance division generated sales of 499.1 million francs for the quarter, a growth of 6.8 percent in francs and 10.7 percent in local currencies, led by double digit growth in Consumer Products and strong growth in Fine Fragrances.

In the division, the compounding business of Fine Fragrances and Consumer Products recorded 12.2 percent increase in sales in local currency, helped by strong volume growth as well as the impact of price increases.

In the quarter, Fine Fragrance sales grew 9 percent. A good growth in Latin America and Europe was partly offset by lower sales in North America that mainly reflected the impact of business erosion. The Consumer Products sales increased 13.2 percent and sales for Fragrance Ingredients grew 1.1 percent - both in local currencies.

Sales in Flavour division increased 3 percent in francs or 6.4 percent in local currency to 561.2 million francs. Sales were boosted by double digit increases of existing products in the developing markets of Asia, Latin America and Africa. New wins in Asia Pacific, Latin America and North America, mainly in Beverages and Snacks, also benefited the results.

Looking ahead over the mid-term, the company said its overall objective is to grow organically between 4.5 percent and 5.5 percent per annum, assuming a market growth of 2-3 percent. The company also projects to continue on the path of market share gains over the next five years.

Givaudan also expects to outgrow the underlying market and to continue to achieve its industry-leading EBITDA margin while improving its annual free cash flow to between 14 percent and 16 percent of sales by 2015.

The company maintained its intention to return above 60 percent of its free cash flow to shareholders. This will be done when the targeted leverage ratio, defined as net debt, divided by net debt plus equity, of 25 percent has been reached, it said.

In Zurich, Givaudan shares closed Tuesday's trading at 863 francs, down 13.50 francs or 1.54 percent.

Register
To receive FREE breaking news email alerts for Givaudan AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.